05/29/2012
In an abstract that will be presented at the American Society of Clinical Oncology annual meeting in Chicago this weekend, researchers report that in patients with platinum-sensitive recurrent serous ovarian cancer, olaparib plus paclitaxel plus carboplatin, followed by maintenance treatment with olaparib, resulted in a significant improvement in progression-free survival compared with paclitaxel plus carboplatin alone.
Previous studies, including one presented at ASCO in 2011, showed that olaparib was useful when given as a maintenance therapy after platinum-based chemotherapy. This new study tested olaparib as part of the initial treatment regimen, as well as for maintenance.
Click here for more information, and here to view the abstract.
